2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.
Immunotherapy still holds the majority of interest in bladder cancer, but there is more to treatments than just immunotherapy, states Black.
The clinical trial field has become very complex as things move upstream, explains Black. There are adjuvant trials before and after radical cystectomy, and trials in non-muscle invasive bladder cancer.
Related Content: